The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): Patient Reported Outcomes at 12-Months
Author(s)
Boye K1, Lebrec J2, Sapin H3, Guerci B4, Giorgino F5, Füchtenbusch M6, Heitmann E7, Orsini Federici M8, Dib A3, García-Pérez LE9
1Eli Lilly and Company, Indianapolis, IN, USA, 2HaaPACS GmbH, Schriesheim, Germany, 3Lilly France SAS, Neuilly-sur-Seine, France, 4University Hospital of Nancy, Nancy, France, 5University of Bari Aldo Moro, Bari, BA, Italy, 6Diabeteszentrum am Marienplatz München, 80331 München, Germany, 7Lilly Deutschland GmbH, Bad Homburg, Germany, 8Eli Lilly Company Italia SpA, Florence, Italy, 9Lilly, S.A., Alcobendas, Spain
OBJECTIVES Patient-reported outcome (PRO) measures provide information that complement clinical data. Studies assessing PRO measures in people living with T2D who initiate injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) medication in routine clinical practice are limited. To better understand the perspectives of people living with T2D regarding their overall health, treatment/device satisfaction, and quality of life and work, here we describe perspectives of participants at the 12-month time-point of TROPHIES. METHODS TROPHIES is 24-month, prospective, non-comparative, observational study on people living with T2D initiating their first injectable glucose lowering agent with once‑weekly dulaglutide (DULA) or once-daily liraglutide (LIRA) conducted in France (n=712), Germany (n=727), and Italy (n=742). Participants’ responses to PRO questionnaires were collected at 12-months and compared to baseline before they initiated treatment with DULA or LIRA. The validated PRO questionnaires include EQ-5D-5L, Impact of Weight on Self Perceptions Questionnaire (IW-SP), Diabetes Treatment Satisfaction Questionnaire-status (DTSQs), Diabetes Productivity Measure (DPM), and Diabetes Injection Device Experience Questionnaire (DID-EQ). For each PRO measure, higher scores reflect better outcomes. Analyses are descriptive in nature due to the non-comparative study design. RESULTS Baseline characteristics (previously published) for participants prescribed DULA (n=1130) or LIRA (n=1051) were similar between groups. The mean change from baseline to 12-months for DULA and LIRA, respectively, for each PRO questionnaire were as follows: EQ-5D-5L index (0.03; 0.04), IW-SP (10.04; 5.77), DTSQs (6.89; 4.40), DPM life productivity (5.27; 3.26), and DPM work productivity (4.46; 2.11). The mean score at 12-months for DID-EQ questionnaires relating to injection device was 88.85 for DULA and 86.34 for LIRA. The sample size for PRO results ranged from 293 to 843. CONCLUSIONS Overall, the data from this varied panel of PRO instruments indicate consistent overall improvements in health reported outcomes in patients initiating and continuing DULA and LIRA at 12-months when compared to baseline.
Conference/Value in Health Info
2021-11, ISPOR Europe 2021, Copenhagen, Denmark
Value in Health, Volume 24, Issue 12, S2 (December 2021)
Code
POSC359
Topic
Health Service Delivery & Process of Care, Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes, Treatment Patterns and Guidelines
Disease
Diabetes/Endocrine/Metabolic Disorders
Explore Related HEOR by Topic
